141 related articles for article (PubMed ID: 37897456)
61. Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis.
Huynh DJ; Renelus BD; Jamorabo DS
BMC Gastroenterol; 2023 Dec; 23(1):450. PubMed ID: 38114915
[TBL] [Abstract][Full Text] [Related]
62. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study.
Chen HY; Huang JY; Siao WZ; Jong GP
Cardiovasc Diabetol; 2020 Jun; 19(1):73. PubMed ID: 32503541
[TBL] [Abstract][Full Text] [Related]
63. Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care.
Tanaka A; Node K
Cardiovasc Diabetol; 2020 Sep; 19(1):132. PubMed ID: 32878601
[TBL] [Abstract][Full Text] [Related]
64. Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
Neuen BL; Arnott C; Perkovic V; Figtree G; de Zeeuw D; Fulcher G; Jun M; Jardine MJ; Zoungas S; Pollock C; Mahaffey KW; Neal B; Heerspink HJL
Diabetes Obes Metab; 2021 Feb; 23(2):382-390. PubMed ID: 33043620
[TBL] [Abstract][Full Text] [Related]
65. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study.
Yu OHY; Dell'Aniello S; Shah BR; Brunetti VC; Daigle JM; Fralick M; Douros A; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ronksley PE; Filion KB; Ernst P; Lix LM;
Diabetes Care; 2020 Oct; 43(10):2444-2452. PubMed ID: 32759360
[TBL] [Abstract][Full Text] [Related]
66. SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study.
Chan GC; Ng JK; Chow KM; Szeto CC
Diabetes Res Clin Pract; 2023 Jan; 195():110200. PubMed ID: 36481225
[TBL] [Abstract][Full Text] [Related]
67. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
[TBL] [Abstract][Full Text] [Related]
68. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
[TBL] [Abstract][Full Text] [Related]
69. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S
ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512
[TBL] [Abstract][Full Text] [Related]
70. Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors.
Wu MZ; Chandramouli C; Wong PF; Chan YH; Li HL; Yu SY; Tse YK; Ren QW; Yu SY; Tse HF; Lam CSP; Yiu KH
Diabetes Metab; 2022 Nov; 48(6):101367. PubMed ID: 35753654
[TBL] [Abstract][Full Text] [Related]
71. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
Li WJ; Chen XQ; Xu LL; Li YQ; Luo BH
Cardiovasc Diabetol; 2020 Aug; 19(1):130. PubMed ID: 32847602
[TBL] [Abstract][Full Text] [Related]
72. A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology.
Mai Z; Li H; Chen G; Chen E; Liu L; Lun Z; Lai W; Zhou C; Yu S; Liu J; Chen S; Chen J; Liu Y
Cardiovasc Drugs Ther; 2022 Aug; 36(4):713-726. PubMed ID: 34028657
[TBL] [Abstract][Full Text] [Related]
73. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
Dawwas GK; Smith SM; Park H
Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
[TBL] [Abstract][Full Text] [Related]
74. How many and who are patients with heart failure eligible to SGLT2 inhibitors? Responses from the combination of administrative healthcare and primary care databases.
Piccinni C; Dondi L; Calabria S; Ronconi G; Pedrini A; Lapi F; Marconi E; Parretti D; Medea G; Cricelli C; Martini N; Maggioni AP
Int J Cardiol; 2023 Jan; 371():236-243. PubMed ID: 36174826
[TBL] [Abstract][Full Text] [Related]
75. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.
Zhuo M; Paik JM; Wexler DJ; Bonventre JV; Kim SC; Patorno E
Am J Kidney Dis; 2022 Jun; 79(6):858-867.e1. PubMed ID: 34762974
[TBL] [Abstract][Full Text] [Related]
76. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
McCoy RG; Dykhoff HJ; Sangaralingham L; Ross JS; Karaca-Mandic P; Montori VM; Shah ND
Diabetes Technol Ther; 2019 Dec; 21(12):702-712. PubMed ID: 31418588
[No Abstract] [Full Text] [Related]
77. Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.
Yang JY; Wang T; Pate V; Gower EW; Crowley MJ; Buse JB; Stürmer T
Diabetes Obes Metab; 2019 May; 21(5):1223-1236. PubMed ID: 30697897
[TBL] [Abstract][Full Text] [Related]
78. Use of sodium-glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation.
Lau D; Pannu N; Yeung RO; Scott-Douglas N; Klarenbach S
CMAJ Open; 2023; 11(1):E101-E109. PubMed ID: 36720493
[TBL] [Abstract][Full Text] [Related]
79. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.
Cardoso R; Graffunder FP; Ternes CMP; Fernandes A; Rocha AV; Fernandes G; Bhatt DL
EClinicalMedicine; 2021 Jun; 36():100933. PubMed ID: 34308311
[TBL] [Abstract][Full Text] [Related]
80. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials.
Fernandes GC; Fernandes A; Cardoso R; Penalver J; Knijnik L; Mitrani RD; Myerburg RJ; Goldberger JJ
Heart Rhythm; 2021 Jul; 18(7):1098-1105. PubMed ID: 33757845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
